Related Experiment Video
Updated: Feb 15, 2026
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
1.2K
Targetable long non-coding RNAs in cancer treatments
Liang Chen1, Emmanuel Enoch Dzakah1, Ge Shan1
1CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui Province 230027, China.
Cancer Letters
|January 18, 2018
Summary
Aberrant expression of long non-coding RNAs (lncRNAs) is linked to cancer development. This review highlights lncRNAs as promising therapeutic targets for cancer treatment due to their critical roles.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant expression of long non-coding RNAs (lncRNAs) is frequently observed in various cancers.
- lncRNAs play critical roles in tumorigenesis and cancer progression.
- Their involvement in physiological and pathological processes makes them potential therapeutic targets.
Purpose of the Study:
- To review well-studied lncRNAs involved in oncogenesis.
- To outline their functions and mechanisms.
- To highlight recent findings relevant to therapeutic interventions.
Main Methods:
- Literature review of scientific publications.
- Analysis of lncRNA functions and mechanisms in cancer.
- Identification of therapeutic potential of lncRNAs.
Main Results:
- Several lncRNAs have been identified as key players in oncogenesis.
- Detailed functional mechanisms of these lncRNAs are elucidated.
- Emerging therapeutic strategies targeting lncRNAs are discussed.
Conclusions:
- lncRNAs are crucial in cancer development and progression.
- Targeting lncRNAs offers a promising avenue for novel cancer therapies.
- Further exploration of lncRNAs as therapeutic targets is warranted.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.7K
3.7K
02:30siRNA - Small Interfering RNAs
18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
02:57piRNA - Piwi-interacting RNAs
7.7K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.7K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K